Biogen seeks FDA approval for Alzheimer’s drug; aims to be first to slow disease
By
Alicia Lasek
Jul 09, 2020
Treatment with aducanumab reduced declines in memory, language, and activities of daily living performance, the drugmaker says.
Clinical briefs for Friday, March 26
By
Alicia Lasek
Mar 26, 2021
California and Florida prepare to open vaccine access to all adults … Common Alzheimer’s treatment linked to slower cognitive decline …Flu shot associated with fewer, less severe COVID cases...
Clinical Briefs for Friday, October 11
By
Alicia Lasek
Oct 10, 2019
Research sheds new light on how brain forms, recalls memories … FDA approves Dexcom G6 Pro continuous glucose monitor … Acute respiratory viral illness surveillance possible in long-term care: study...
FDA advisers vote ‘no’ on drug that may slow Alzheimer’s progression
By
Alicia Lasek
Nov 09, 2020
If approved by the FDA, aducanumab would be the first-ever drug marketed to slow progression of the brain-wasting disease, according to its developer. But an advisory committee was unconvinced of the drug’s...
Study: ‘Cognitive frailty’ may be result of aging — not the brain changes found in dementia
By
Alicia Lasek
Jan 11, 2022
Reduced cognitive function without substantial memory complaints may be a normal part of aging and not an early sign of Alzheimer’s disease or other dementias, investigators say.
Highly accurate Alzheimer’s blood test a ‘breakthrough,’ observers say
By
Alicia Lasek
Jul 30, 2020
The experimental blood test rivals the accuracy of standard diagnostic methods and may soon prove to be a cost-effective, accessible tool in the clinical setting, according to some in the scientific community.
NIH highlights decade of Alzheimer’s advancements tied to small business investments
By
Alicia Lasek
Aug 11, 2021
A new paper showcases the results of 11 years of federal investment in dementia research, including advancements in care intervention, diagnostics and therapeutics.
Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
Generic for Viagra holds promise as Alzheimer’s disease treatment, Cleveland Clinic researchers say
Dec 08, 2021
Users of sildenafil are 69% less likely to develop Alzheimer’s disease than their peers who do not use the drug, investigators report. A clinical trial to confirm its benefits for Alzheimer’s patients...